Life Sciences Archive » July, 2024

Life Sciences - July, 2024

297 articles

• Del. Justices Reject New Earnout Claim In $300M Deal Appeal
• 2nd Circ. Paves Way For Conn. Zantac Bellwether, Attys Say
• AI Prior Art Is Either Nothing New Or A Red Flag, USPTO Told
• Del. Judge Clears Lupin's Generic Kidney Disease Drug
• Novartis Says FDA Wrongly OK'd Generic Heart Drug
• Inhaler Patents 'Must Be' In Orange Book, Teva Tells Fed. Circ.
• How To Grow Marketing, Biz Dev Teams In A Tight Market
• 1st Circ. Mostly Backs $5M Award In Biotech Recruiting Spat
• 5 Trials To Watch In The 2nd Half Of 2024
• AIG Units Off Hook In Defending McKesson Opioid Suits
• Life Sciences Cases To Watch 2024: A Midyear Report
• 2024 Product Liability Areas To Watch
• Cook Medical Vein Filter Claims Came Too Late, 7th Circ. Says
• DC Circ. Finds NIH's Comment Restrictions Unconstitutional
• AIDS Org Sues Express Scripts For PBM Monopoly
• Judge Wants Device Warning Answers From Mich. Justices
• Chancery Rejects Forte-Camac Deal As 'Not Fair' To Class
• Psychedelics And The Law: A Midyear Review
• Patent Lessons From 5 Federal Circuit Reversals In June
• DOD Contractors Must Face Suit Over 'Made In U.S.A.' Label
• Unpacking HHS' Opinion On Cell Therapy Refund Programs
• Rock Climbing Makes Me A Better Lawyer
• Litigator Rejoins Faegre Drinker From Medical Device Co.
• What Mass. Attys Will Be Watching In The 2nd Half Of 2024
• Genzyme Says Sarepta's Dystrophy Gene Therapy Infringes IP
• Medical Co. Can't Get Alleged Fraudulent Arbitral Award Nixed
• NIST Lays Out 200+ Ways To Tackle Generative AI Risks
• Wash. Says At-Home Rape Kit Law Targets Harm, Not Speech
• Gilstrap Finds Nothing Between The Lines Of Barcode Patents
• Vaccine Co. Was Sanctioned For Deliberately Hiding Testing
• Boehringer Appeals HHS Win In Medicare Drug Price Suit
• Kirkland-Led Amulet Closes $1.2B Health-Focused Fund
• Think Like A Lawyer: Dance The Legal Standard Two-Step
• Alice Step 2 Trends Show Courts' Extrinsic Evidence Reliance
• Recent Settlement Shows 'China Initiative' Has Life After Death
• Legalization Org Taps Cannabis Atty As New Treasurer
• GSK Settles Ill. Zantac Cancer Suit
• Firm, Ex-Client Brief Conn. High Court In Punitive Award Case
• Catching Up With Delaware's Chancery Court
• DOJ Innovasis Settlement Offers Lessons On Self-Disclosure
• How Orange Book Antitrust Scrutiny Is Intensifying
• Ex-Pharma Exec Seeks Leniency After SEC Contempt Plea
• 'Low-Grade Lawyering': Quinn Emanuel Attys Draw Judge's Ire
• Apple Commits To White House Guidelines For Responsible AI
• Product Liability Cases To Watch 2024: A Midyear Report
• Weight-Loss Drugs May Spur Next Major Mass Tort
• Del. Court Won't Let Generic Co. Walk Back Invalidity Promise
• Indivior To Pay $86M To Settle Opioid Claims By 5 States
• Hearing Set Over Bid To Recuse Judge In Philly Zantac Cases
• UK Litigation Roundup: Here's What You Missed In London
• 3rd Circ. Again Tosses J&J Talc Unit's 'Texas Two-Step' Ch. 11
• Seattle, Monsanto Ink $160M Deal Over PCBs In Duwamish
• Pfizer Calls GSK Patents In COVID Vax Case Unenforceable
• DC Panel Upholds FDA's Win Against Ipsen's Generics Suit
• Shkreli Says He Has Right To Use Wu-Tang Clan Album Copies
• Ex-Pharma Exec's Counsel Accused Of Reading Stolen Emails
• Loeb & Loeb Says Ex-GC's Sanctions Motion Is Bogus
• Deals Rumor Mill: Wiz-Google, Daily Telegraph, Medline IPO
• Clinic Drops Case Against Maker Of Body-Sculpting Devices
• Rite Aid's Elixir Buyer Must Pay Additional $50M In Ch. 11 Sale
• The FTC Needs To Challenge The Novo-Catalent Deal
• After Chevron: Slowing Down AI In Medical Research
• Patent Cap In Drug Pricing Bill Seen As Having Muted Effect
• McCarter & English Beats Biotech Malpractice Suit In NJ
• Ex-Pharma Exec Gets Jail For Insider Trading On Kodak Loan
• Priest Loses Fee Bid After 'Split Baby' SEC Verdict
• Being A Luthier Makes Me A Better Lawyer
• Meet The Lead Ozempic Lawyers
• Wash. AG Says 'Abortion Reversal' Clinic's Suit Still Deficient
• $680M Allergan FCA Suit Tossed After High Court Revival
• Invitae's Ch. 11 Plan Needs Tweaking, Judge Says
• 4th Circ. Says Bad Jury Instructions Gave J&J Win In Mesh Suit
• Ex-Celgene Exec Off The Hook For Statements To Investors
• Feds Urge 6th Circ. To Affirm Pharma Owner's Fraud Sentence
• Chancery Slams 'Squishy' Deal In 'Tagalong' BioMarin Suit
• Split 2nd Circ. Keeps Zantac Suits In Conn. State Court
• FDA's Multifaceted Role On Display In MDMA Therapy Scrutiny
• Lead Like 'Ted Lasso' By Embracing Cognitive Diversity
• Senate Dems Roll Out Bill To Codify Chevron Deference
• 4 Firms Guide SPAC Mergers Targeting AI, Cannabis Sectors
• GSK Inks $4.5M Deal Resolving 'Non-Drowsy' Robitussin Suit
• AbbVie Challenges Mo. Drug Discount Program Requirements
• USPTO Wins Dismissal Of Danish Co.'s PTSD Drug Lawsuit
• Tevra Says Bayer Owes Millions As Antitrust Trial Opens
• Allarity Warns Of SEC Suit Over Cancer Drug Statements
• Michigan's Cases To Watch 2024: A Midyear Report
• Price-Fixing Claims Against Par Pharma On Chopping Block
• How Cos. Should Handle Research Org.'s Carcinogen Evals
• DuPont, NC To Drop Docs Dispute In 'Forever Chemicals' Case
• Groups Ask 3rd Circ. To Reverse Medicare Drug Price Rulings
• Anthem Blue Cross Wants Lab's $3.8M Suit Tossed
• 1st Circ. Hints At Higher Bar For Feds In Anti-Kickback Cases
• Lack Of 'Smoking Gun' Sinks J&J's Bid To DQ Beasley Allen
• Catching Up With Delaware's Chancery Court
• Jazz Says Narcolepsy Drug Charge MDL Should Be Tossed
• House IP Committee Heads Unveil Drug Pricing Bill
• Splenda Must Face False Ad Suit Over Diabetes Benefits
• Conn. Hospital Didn't Heed Insulin Pen Warnings, Maker Says
• Boehringer Looks To Toss Inhaler Antitrust Case
• Boehringer Long Ignored Zantac's Cancer Signs, Jury Hears
• Amazon Gets Tainted Eye Drop Suit Pared Down
• A Guide To The USPTO's Long List Of Requests For Comment
• McCarter & English Pushes To End Biotech Malpractice Row
• Gout-Focused Biotech Raises $60M In Latest Funding Round
• Analyzing FDA Draft Guidance On Clinical Trial Diversity
• Ex-Pharma Sales Exec Denies Fake Prescription Scheme
• Regeneron Rips DOJ's FCA Suit As 'Divorced From Reality'
• Cooley, Latham Lead Biotech Firm Artiva's Upsized $167M IPO
• What's New In The AI Healthcare Regulatory Space
• Del. Dispatch: 27.6% Stockholder Not A Controller
• DaVita To Pay $34M In Medicare Kickback Whistleblower Suit
• Abbott Wins Trust Asset Freeze To Collect $33M In TM Fight
• Apple Wants 2 Trials In Masimo Trade Secrets And Patent Row
• Vidal Backs 'Egregious Abuse' Findings Against Vaccine Maker
• Biopharma Shareholder Sues In Del. For Docs On Akeso Deal
• LegitScript Asks 9th Circ. To Ax Price-Checker Antitrust Suit
• Ocugen Execs Hit With Derivative Suit Over Shoddy Controls
• GSK, Boehringer Face Jurors Again On Zantac Cancer Claims
• Docs Get Same Hefty Opioid Sentences Despite Top Court Win
• Pharma Biz Buys Animal Medicine Co. For Up To $520M
• Ga. Mineral Co. Can't Nab Win In Row Over Talc Suit Coverage
• PharMerica Inks $100M Deal In 13-Year-Old Whistleblower Suit
• ITC Affirms Lab Equipment Co.'s Patent Wasn't Infringed
• Many AI Patent Eligibility Issues Still Hazy After Guidance
• Pharma Co. Slams Magistrate's Venue Report In Opioid Suit
• Chancery Again Spikes Biopharm Board Pay Deal, $600K Fee
• Hospital Trims Its Insulin Pen Claims Against Novo Nordisk
• Ex-Genentech Worker Seeks Revival Of 401(k) Investment Suit
• 3 Policyholder Tips After Calif. Ruling Denying D&O Coverage
• 1 Year At The UPC: Implications For Transatlantic Disputes
• Boehringer Wants Inhaler Antitrust Case Moved To Mass.
• Bruised SPAC Market Pins Revival Hopes On Veteran Backers
• Now More Than Ever, Lawyers Must Exhibit Professionalism
• ADA Can't Shield Worker From Failed Drug Test, Co. Says
• Gilead Asks Calif. Supreme Court To Ax 'Disastrous' Decision
• UPC Knocks Out Amgen's Cholesterol Drug Patent
• Chancery Orders Illumina Docs Released In Grail Merger Fight
• Tycoon's Pilot Says Feds' Stock Tip Claims Don't Add Up
• FDA Vet Joins Arnold & Porter As Counsel On Healthcare
• Drugmaker BioLineRx Beats Investor Suit Over Cash Shortfall
• 3rd Circ. Backs Tossing Over 1K Suits In Merck Vaccine MDL
• High Court Made Profound Mistake In Tossing Purdue Deal
• Manatt Adds Healthcare Transactions Partner From McDermott
• Heart-Focused Biotech Closes $260M Series B Funding Round
• Ex-CBD Exec Gets $533K In Fla. Investment Fraud Suit
• Vertex Pharma Widens War On Watchdog's Kickback Views
• The 2024 Diversity Snapshot: What You Need To Know
• These Firms Have The Most Diverse Equity Partnerships
• Serving In The National Guard Makes Me A Better Lawyer
• Big Business May Come To Rue The Post-Administrative State
• Acuitas Seeks Credit For IP Tied To COVID Vax
• Ex-Pfizer Worker Seeks No Time For Paxlovid Insider Trading
• Walgreens Investor Sues Over Challenged Pharmacy Division
• AbbVie Can't Keep CoolSculpting Suit In NJ Fed Court
• Theranos Ex-Exec's Lead Atty Joins Boutique Firm In LA
• Proposed Terminal Disclaimers Rule Harms Colleges, Startups
• Catching Up With Delaware's Chancery Court
• Health Services Spinoff Leads 3 IPO Launches Totaling $1.1B
• A Midyear Forecast: Tailwinds Expected For Atty Hourly Rates
• Law360 Names 2024's Top Attorneys Under 40
• Del. Court Finds 1 Of 6 Bylaws Invalid But All Unenforceable
• AI Drugmaker BioXcel Beats Investor Fraud Suit, For Now
• Whistleblower's Attys Get $5.9M After Losing $11.5M Fee Ask
• Opioid MDL Plaintiffs Atty Fee Awards Upheld
• Plaintiffs Want Opioid MDL Bellwethers Cut For Lost Emails
• Fed. Circ. Upholds Natera's Injunction In Cancer Test IP Fight
• Fed. Circ. Probes Case With Apple Watch Import Ban At Stake
• Judge Denies Go-Ahead For Suit Over Invitae Refi Deal
• No Injury In Suit Targeting J&J Asset Shuffles, Talc Unit Says
• Zimmer Biomet Owes Despite Expired Patents, 7th Circ. Says
• Chancery Tosses Centene Shareholders' Medicaid Fraud Suit
• Widower Drops Suit Over Surgical Robot-Related Death
• Ex-Quantix Worker Sues Abbott Labs Over Drug Test Firing
• AbbVie Brings Atty-Client Privilege Fight To Supreme Court
• Ex-Magellan Execs Waive Conflicts Over Past Shared Counsel
• Senate Clears Patent Bill Aiming To Lower Drug Prices
• Pfizer's $50M EpiPen Deal Gets Final OK In Antitrust Suit
• IP Forecast: Napa Winery's Ex-Atty Wants Another Trial
• Judge Won't Dismiss Cannabis Extraction IP Dispute
• DC Judge Questions Pharma Co.'s Generic Harm In FDA Spat
• Fed. Circ. Pauses Ouster Of Teva Patents From Orange Book
• Critical Questions Remain After High Court's Abortion Rulings
• Opiate MDL Judge Flags Evidence Preservation Shortfall
• A Look At Acquisition Trends For Radiopharmaceuticals
• GSK Asks Judge To Rule In Teva IP Case, Citing Opioid Deals
• States Should Loosen Law Firm Ownership Restrictions
• Talc Law Firms Beat J&J Subpoenas Seeking Funding Info
• Deals Rumor Mill: Saudi Aramco, Paramount Global, Carlyle
• Orrick Adds Wilson Sonsini, Hooper Lundy Healthcare Attys
• Patent Cases To Watch In The Second Half Of 2024
• Roundup Cancer Case Revived By Oregon Appellate Panel
• Drug Pricing, Overreach Dominate IP Disclaimer Feedback
• Medical Imaging Co. Looking To Vacate 'Tainted' Award
• ​GOP Bombards Agencies With Demands After Chevron's End
• Meijer Says Takeda Can't Force Antitrust Suit Into Arbitration
• Skin Care Tech Co. Says Suit Shows 'Rough' Year, Not Fraud
• Buyers Say Teva Had Multipart Scheme To Delay Inhaler Rivals
• Navigating FDA Supply Rule Leeway For Small Dispensers
• RJ Reynolds Urges Toss Of Menthol Suit Against FDA
• Ex-FDA Regulator Joins Chicago Boutique Amin Wasserman
• Longtime Axinn Atty To Chair Polsinelli's Hatch-Waxman Team
• Solving Puzzles Makes Me A Better Lawyer
• Ex-CEO Convicted In COVID Test Kit Fraud Case
• Pharma Co. Fined $16.9M For Fake Scripts, Ex-VP Arrested
• Bard Fights 'Patent Misuse' Ruling In $53M Suit At 9th Circ.
• South Africa Drops J&J Probe After TB Drug Price Cuts
• Fla. Judge Won't Nix Antitrust Claims Against Alcon
• HEC Can't Get Damages Over Injunction In Novartis Feud
• BCBS Unit Fails To Stop Religious Vaccine Objector Suits
• 3rd Circ. Rips 2nd Circ. In Asset Freeze Ruling For SEC
• NJ Panel Revokes Coverage For Pharma Co. In Fraud Row
• Purdue Plans 'High-Speed' Bid For New Ch. 11 Plan
• NJ Jury Begins Deliberating COVID Test Kit Fraud Case
• Terrorism Victims Push To Keep Pharma Suit In DC Circ.
• FTC Says Drug Middlemen Inflate Costs, Squeeze Pharmacies
• Gov't Missed Merck Vax Potency Problem, 3rd Circ. Told
• Texas Ethics Opinion Flags Hazards Of Unauthorized Practice
• 6 Lessons From DOJ's 1st Controlled Drug Case In Telehealth
• After Chevron: Scale Tips Favor Away From HHS Agencies
• Emergent, J&J Reach $50M Deal In COVID Vax Supply Fight
• Biotech Slaps Intellia With IP Suit Over $100M Regeneron Deal
• Jurors Told To Decide Who Is Lying In COVID Test Fraud Case
• Blank Check Co. Sagaliam Gets Shareholder Suit Trimmed
• Purdue Creditors Look To Sue Sacklers After Justices' Ruling
• Biotech Co. Alleges Arbitrator Conflict In Patent Award Fight
• Ex-Ga. Insurance Chief Wants Lighter Term In Kickback Case
• Kirkland, Fenwick Steer Lilly's $3.2B Morphic Acquisition
• 2 Options For Sackler Family After High Court Purdue Ruling
• In Memoriam: The Modern Administrative State
• After Chevron: Expect Limited Changes In USPTO Rulemaking
• Rite Aid Says Elixir Buyer In Contempt Over Liability Dispute
• Catching Up With Delaware's Chancery Court
• The Biggest Patent Rulings Of 2024: A Midyear Report
• How Reshaped Circuit Courts Are Faring At The High Court
• Breaking Down The Vote: The High Court Term In Review
• High Court Flexes Muscle To Limit Administrative State
• The Sharpest Dissents From The Supreme Court Term
• 5 Moments That Shaped The Supreme Court's Jan. 6 Decision
• The Funniest Moments Of The Supreme Court's Term
• 2024 Global M&A, Mega-Deal Values Outpacing 2023
• The Firms That Won Big At The Supreme Court
• Novartis Allegedly Sat On Drug Rights To Avoid $1B Payment
• How High Court Approached Time Limit On Reg Challenges
• 3rd Circ. Preview: Ponzi Scheme, Merck Vaccine Heat Up July
• Fed. Circ. Skinny Label Ruling Guides On Infringement Claims
• Top Federal Tax Cases To Watch In The 2nd Half Of 2024
• A&O Shearman-Led GSK Signs €1.4B Deal For Vaccines
• 4 Takeaways From Biotech Patent Invalidity Ruling
• How To Clean Up Your Generative AI-Produced Legal Drafts
• HHS Scores Early Win In Boehringer's Medicare Pricing Suit
• Humana Drops 6th Circ. Remand Bid In Ohio Collusion Suit
• Roche Says Stanford Profs Stole Cancer Detection Tech
• Revived Skinny Label Case Is A Warning For Generics
• Appeals Board Tosses Revived License Breach Dispute
• Calif. Ruling Heightens Medical Product Maker Liability
• Cooley DQ'd From IP Case Over Atty's Past Patent Work
• Constitutional Protections For Cannabis Companies Are Hazy
• Penile Implant Doc Seeks $7M Atty Fees, Costs In $18M IP Win
• 4 Mass. Rulings You Might Have Missed In June
• 1st Circ. Hands Hearing Loss Biotech Win In Stock-Drop Suit
• Cerevel Investors Allege Insider Trades Pre-$8.7B AbbVie Deal
• USPTO Disclaimer Rule Would Complicate Patent Prosecution
• After Chevron Deference: What Lawyers Need To Know
• Chancery Tosses Challenge To $3B AstraZeneca Viela Bio Sale
• Quest Diagnostics Paying $985M For OMERS' LifeLabs
• Boxing Makes Me A Better Lawyer
• FTC Investigating Teva Inhaler Patent Listings, Report Says
• Chamber, Pharma Slam Colorado Drug Price Controls
• Biotech Biz Co-Directors Sue Each Other In Del., Cite Breaches
• Purdue Ch. 11 Ruling Reinforces Importance Of D&O Coverage
• Pharma Co. Scores Exit In Investor Suit Over Primate Imports
• McKinsey Wants To Arbitrate Ex-Partner's Defamation Suit
• Beasley Allen Slams J&J's DQ Bid 'Check-Up' In Talc Tort
• Industry Self-Regulation Will Shine Post-Chevron
• 3 Ways Agencies Will Keep Making Law After Chevron
• After Chevron
• High Court Agrees To Review FDA's Flavored E-Cig Denial
• High Court's 1-2 Punch Sets Up Long-Standing Regs For KO
• UC Riverside Profs Win Combined $6.1M In Retaliation Trial
• State AGs Get Stay Lifted In Generic Drug Pricing Litigation
• IPO Rebound Leads Capital Markets Recovery At Midyear
• Caribou Bio Inks $3.9M Deal In Investors' Cancer Therapy Suit
• NJ Judge Tosses J&J Unit's Libel Claim Over Talc Study
• After Chevron: Expect Few Changes In ITC Rulemaking
• Bard, Hernia Mesh Claimants Can't Hide Injury MDL Deal Info
• 6 PTAB Events To Know From The Last 6 Months
• Talc Victims Can't Block J&J From Filing For Ch. 11 Outside NJ
• GSK Wants Lab's Zantac Whistleblower Suit Moved To Florida
• Atty Well-Being Efforts Ignore Root Causes Of The Problem
• Parsing Justices' Toss Of Purdue's Controversial Ch. 11 Plan
• Catching Up With Delaware's Chancery Court
• Manatt Managing Partner Begins Second 5-Year Term
• Apple Scores Some Patent Board Reviews In Watch IP Fight
• AbbVie Hit With Age, Gender Bias Suit By Former Salesman
• Ardian Raises $3.2B For 6th Co-Investment Fund
• Feds Say Ex-Magellan Officer's Atty May Have Conflict
• Supreme Court Widens Window To Challenge Federal Regs